Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) VP Robert W.A. Sellers sold 8,850 shares of Edwards Lifesciences Corp stock in a transaction dated Thursday, July 31st. The stock was sold at an average price of $91.47, for a total transaction of $809,509.50. Following the completion of the transaction, the vice president now directly owns 12,509 shares in the company, valued at approximately $1,144,198. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Friday, hitting $91.97. The stock had a trading volume of 1,899,876 shares. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $94.50. The stock’s 50-day moving average is $85.98 and its 200-day moving average is $77.78. The company has a market cap of $9.712 billion and a price-to-earnings ratio of 13.02.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.28 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $90.00.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.